Gregory  Grunberg net worth and biography

Gregory Grunberg Biography and Net Worth

Director of 89bio
Gregory Grunberg, M.D. has served as a member of our board of directors since April 2018. Dr. Grunberg has been a Managing Director at Longitude Capital Management Co., LLC, a venture capital firm, since February 2012. Prior to joining Longitude, Dr. Grunberg was a Principal at Rho Ventures, a venture capital firm, where he worked from May 2007 to January 2012. Dr. Grunberg maintains a limited clinical practice in internal medicine and affiliations with University of California, San Francisco and Kaiser Permanente. Dr. Grunberg has served on the boards of Kala Pharmaceuticals Inc., a pharmaceutical company, since April 2016, and WelbeHealth LLC, a private healthcare services company, since April 2018. He has served as a board observer at Sydnexis, Inc., an private biotechnology company, since September 2017. He previously served on the board of California Cryobank (acquired by GI Partners) from August 2014 to August 2018 and led Longitude’s investment in Practice Fusion (acquired by Allscripts Healthcare Solutions, Inc.). While at Rho Ventures he served on the board of AqueSys Inc. (acquired by Allergan plc) from June 2010 to December 2011 and was a board observer at both SARCode Bioscience Inc. (acquired by Shire plc) from June 2011 to February 2012 and PHT Corporation (acquired by eResearchTechnology, Inc.) from November 2010 to November 2012. Dr. Grunberg earned his M.D. and M.B.A. from Duke University and his A.B. in Economics and English from Amherst College.

How do I contact Gregory Grunberg?

The corporate mailing address for Dr. Grunberg and other 89bio executives is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. 89bio can also be reached via phone at 415-432-9270 and via email at [email protected]. Learn More on Gregory Grunberg's contact information.

Has Gregory Grunberg been buying or selling shares of 89bio?

Gregory Grunberg has not been actively trading shares of 89bio during the past quarter. Most recently, Gregory Grunberg sold 850 shares of the business's stock in a transaction on Wednesday, April 21st. The shares were sold at an average price of $27.60, for a transaction totalling $23,460.00. Learn More on Gregory Grunberg's trading history.

Who are 89bio's active insiders?

89bio's insider roster includes Gregory Grunberg (Director), Ryan Martins (CFO), Rohan Palekar (CEO), Ollin Sykes (Director), and Ram Waisbourd (Insider). Learn More on 89bio's active insiders.

Are insiders buying or selling shares of 89bio?

In the last twelve months, 89bio insiders bought shares 2 times. They purchased a total of 1,356,250 shares worth more than $20,745,125.00. In the last twelve months, insiders at the sold shares 6 times. They sold a total of 60,631 shares worth more than $1,073,288.10. The most recent insider tranaction occured on March, 4th when Director Ra Capital Management, L.P. bought 1,350,000 shares worth more than $20,722,500.00. Insiders at 89bio own 4.4% of the company. Learn More about insider trades at 89bio.

Information on this page was last updated on 3/4/2024.

Gregory Grunberg Insider Trading History at 89bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/21/2021Sell850$27.60$23,460.00View SEC Filing Icon  
See Full Table

Gregory Grunberg Buying and Selling Activity at 89bio

This chart shows Gregory Grunberg's buying and selling at 89bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

89bio Company Overview

89bio logo
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $11.64
Low: $11.03
High: $11.68

50 Day Range

MA: $10.98
Low: $8.13
High: $13.77

2 Week Range

Now: $11.64
Low: $6.57
High: $22.93

Volume

840,202 shs

Average Volume

1,679,862 shs

Market Capitalization

$1.09 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04